Drugs / HypoSti.CAR-HER2 T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05681650 | Oct 2023 → Dec 2025 overdue | HER2 positive breast carcinoma | Chinese PLA General Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HypoSti.CAR-HER2 T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05681650 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor modified T (CAR-T) cell therapy” NCT05681650 ↗ |